| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | Opdivo® is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults. |
| Assessment Process | |
| Rapid review commissioned | 02/07/2015 |
| Rapid review completed | 16/07/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 30/10/2015 |
| NCPE assessment completed | 10/03/2016 |
The HSE has approved reimbursement following confidential price negotiations September 2018
